Navigation Links
Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
Date:8/30/2007

- Findings Published in Blood -

SAN DIEGO, Aug. 30 /PRNewswire/ -- Novocell Inc., a stem cell engineering company, today announced research findings that for the first time identify two prominent cancer cell signaling pathways as essential for the efficient proliferation and self-renewal of human embryonic stem cells (hESCs). The findings were prepublished online August 29, 2007 in Blood First Edition Paper titled "Self-Renewal of Human Embryonic Stem Cells Requires Insulin-like Growth Factor-1 Receptor and ERBB2 Receptor Signaling."

Researchers studying the self-renewal of hESCs discovered a link with insulin-like growth factor-1 (IGF-1R), and ERBB2/3. Both pathways are highly implicated in cancer and the target of numerous oncology therapeutics. EBRR2 is often overexpressed in breast cancer and other malignancies and is the target of the monoclonal antibody Herceptin. Researchers from Novocell, Invitrogen and the University of Washington collaborated on the published study.

"These new findings indicate for the first time that the major signaling pathways driving the self-renewal of human embryonic stem cells are also key pathways that signal inappropriately in a number of different cancers," said Allan Robins, Ph.D., senior author and Vice President and Chief Technical Officer of Novocell. "Such a linkage provides an avenue for Novocell to potentially identify new targets for oncology therapeutics using human embryonic stem cells."

"The implication that key cancer pathways are associated with human stem cell proliferation and self-renewal is yet another exciting outgrowth from the extensive stem cell research at Novocell that includes our defined media STEMPRO(R) hESC SFM licensed exclusively to Invitrogen and our cell therapy for diabetes," said Alan Lewis, Ph.D., President and CEO of Novocell.

About Novocell

Novocell Inc. is a stem cell engineering company with research operations in San Diego, CA, and Athens, GA, dedicated to creating, delivering, and commercializing cell and drug therapies for diabetes and other chronic diseases. Novocell is the first company to efficiently engineer human embryonic stem cells into definitive endoderm, the gatekeeper cells that differentiate into many other cells, tissues and organs. Novocell has three primary technologies: stem cell engineering, cell encapsulation, and drug discovery. The company was founded in 1999, merged with CyThera and BresaGen in 2004 and completed a $25M Series C financing in July 2007. For more information, visit http://www.novocell.com.


'/>"/>
SOURCE Novocell Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
Breaking Biology News(10 mins):